RxDoctor Payments Data

Angela Deweese, MD

Family Medicine · Evansville, INNPI 1679641161

Payments from drug & device makers

$4,697in general payments, 2019–2025

Across 302 payments — averaging $15.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$355
  • Pfizer$350
  • GSK$348
  • Amgen$327
  • Otsuka America Pharmaceutical, Inc.$265
  • plus $2K from 40 others

What the payments were for

  • Food & beverage$4,697100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,697 in reported general payments places this provider in the 85th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$175,910
Medicare patients
280
Services billed
3,603

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide81$109,614
FarxigaDapagliflozin Propanediol70$70,588
EliquisApixaban65$56,626
MounjaroTirzepatide42$45,923
JardianceEmpagliflozin45$39,010
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$35,736
TrulicityDulaglutide21$34,092
JanuviaSitagliptin Phosphate19$23,166
Repatha SureclickEvolocumab21$22,901
Breo ElliptaFluticasone/Vilanterol34$19,629
XareltoRivaroxaban17$16,303
MyrbetriqMirabegron16$10,642
LinzessLinaclotide18$10,463
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog19$6,728
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$6,624

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$355$109,61481 claims
Lilly USA, LLCMounjaro, Trulicity$164$80,01563 claims
AstraZenecaFarxiga$71$70,58870 claims
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$348$57,85286 claims
PfizerEliquis$350$56,62665 claims
Boehringer IngelheimJardiance$202$39,01045 claims
MerckJanuvia$96$23,16619 claims
Johnson & JohnsonXarelto$24$16,30317 claims
AbbVieLinzess, Synthroid$1,111$12,92858 claims
Astellas Pharma US IncMyrbetriq$17$10,64216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Evansville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →